RO111991B1 - Metoda de tratament al hepatitei c si compozitie farmaceutica pentru tratare - Google Patents

Metoda de tratament al hepatitei c si compozitie farmaceutica pentru tratare Download PDF

Info

Publication number
RO111991B1
RO111991B1 RO94-00409A RO9400409A RO111991B1 RO 111991 B1 RO111991 B1 RO 111991B1 RO 9400409 A RO9400409 A RO 9400409A RO 111991 B1 RO111991 B1 RO 111991B1
Authority
RO
Romania
Prior art keywords
thymosin
interferon
treatment
hepatitis
patients
Prior art date
Application number
RO94-00409A
Other languages
English (en)
Romanian (ro)
Inventor
Paul Chretian
Milton Mutchnick
Kenneth E Sherman
Original Assignee
Alpha 1 Biomedicals Inc
Milton Mutchnick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha 1 Biomedicals Inc, Milton Mutchnick filed Critical Alpha 1 Biomedicals Inc
Publication of RO111991B1 publication Critical patent/RO111991B1/ro

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2292Thymosin; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
RO94-00409A 1991-09-13 1992-09-08 Metoda de tratament al hepatitei c si compozitie farmaceutica pentru tratare RO111991B1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75954491A 1991-09-13 1991-09-13
PCT/US1992/007556 WO1993005806A1 (en) 1991-09-13 1992-09-08 Composition and method of treating hepatitis c

Publications (1)

Publication Number Publication Date
RO111991B1 true RO111991B1 (ro) 1997-04-30

Family

ID=25056052

Family Applications (1)

Application Number Title Priority Date Filing Date
RO94-00409A RO111991B1 (ro) 1991-09-13 1992-09-08 Metoda de tratament al hepatitei c si compozitie farmaceutica pentru tratare

Country Status (23)

Country Link
US (3) US6001799A (US07384924-20080610-C00031.png)
EP (1) EP0603305B1 (US07384924-20080610-C00031.png)
JP (1) JP3228512B2 (US07384924-20080610-C00031.png)
KR (1) KR100254082B1 (US07384924-20080610-C00031.png)
AT (1) ATE152914T1 (US07384924-20080610-C00031.png)
AU (1) AU667327B2 (US07384924-20080610-C00031.png)
CA (1) CA2119006C (US07384924-20080610-C00031.png)
CZ (1) CZ286827B6 (US07384924-20080610-C00031.png)
DE (1) DE69219782T2 (US07384924-20080610-C00031.png)
DK (1) DK0603305T3 (US07384924-20080610-C00031.png)
ES (1) ES2103966T3 (US07384924-20080610-C00031.png)
FI (1) FI107879B (US07384924-20080610-C00031.png)
GR (1) GR3024025T3 (US07384924-20080610-C00031.png)
HK (1) HK1021687A1 (US07384924-20080610-C00031.png)
HU (1) HU221006B1 (US07384924-20080610-C00031.png)
MX (1) MX9205240A (US07384924-20080610-C00031.png)
NO (1) NO941310L (US07384924-20080610-C00031.png)
RO (1) RO111991B1 (US07384924-20080610-C00031.png)
RU (1) RU2104010C1 (US07384924-20080610-C00031.png)
SG (1) SG64897A1 (US07384924-20080610-C00031.png)
TW (1) TW224053B (US07384924-20080610-C00031.png)
WO (1) WO1993005806A1 (US07384924-20080610-C00031.png)
ZA (1) ZA926964B (US07384924-20080610-C00031.png)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (US07384924-20080610-C00031.png) * 1991-09-13 1994-05-21 Paul B Chretien
SG64892A1 (en) * 1992-02-06 1999-05-25 Sciclone Pharmaceuticals Method for treating hepatitis b carriers with minimal disease
WO1994001125A1 (en) * 1992-07-13 1994-01-20 Sherman Kenneth E Composition and method of treating hepatitis b
AU751199B2 (en) * 1992-07-13 2002-08-08 Government Of The United States Of America As Represented By The Secretary Of The Army Composition and method of treating hepatitis B
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
TW249754B (US07384924-20080610-C00031.png) * 1993-10-26 1995-06-21 Alpha I Biomedicals Inc
EP0731710B1 (en) * 1993-11-05 2003-05-14 Alpha 1 Biomedicals, Inc. Thymosine alpha 1 containing compositions for the treatment of patients having decompensated liver disease
JP3837769B2 (ja) * 1995-06-12 2006-10-25 大塚製薬株式会社 抗ウイルス剤
KR100394382B1 (ko) * 1996-02-28 2004-02-05 유니하트 코포레이션 천연사람α-인터페론으로구성된약학조성물
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AU2001272923A1 (en) 2000-05-26 2001-12-11 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
CN1446096A (zh) * 2000-08-07 2003-10-01 希克龙制药公司 使用胸腺素、干扰素和利巴韦林治疗丙型肝炎
AU2002227252A1 (en) * 2000-12-01 2002-06-11 Cornell Research Foundation Animal model for flaviviridae infection
EP1435974A4 (en) * 2001-09-28 2006-09-06 Idenix Cayman Ltd METHOD AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS WITH 4'-MODIFIED NUCLEOSIDES
US20050013801A1 (en) * 2001-10-05 2005-01-20 Hsu Henry H. Methods of treating liver fibrosis and hepatitis c virus infection
EA006743B1 (ru) 2001-10-26 2006-04-28 Роуд Айлэнд Хоспитал Стимуляция тимозином генетической иммунизации
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
CA2476279A1 (en) * 2002-02-14 2003-08-21 Lieven J. Stuyver Modified fluorinated nucleoside analogues
CN103319554A (zh) 2002-06-28 2013-09-25 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
US7662798B2 (en) 2002-06-28 2010-02-16 Idenix Pharmaceuticals, Inc. 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
JP2006519753A (ja) 2002-11-15 2006-08-31 イデニクス(ケイマン)リミテツド 2’−分枝ヌクレオシドおよびフラビウイルス科ウイルス突然変異
ES2470771T3 (es) 2002-12-12 2014-06-24 Idenix Pharmaceuticals, Inc Procedimiento para la producción de nucle�sidos ramificados en 2'
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
JP4149296B2 (ja) * 2003-03-26 2008-09-10 株式会社ルネサステクノロジ 半導体記憶装置
DE602004027127D1 (de) * 2003-03-28 2010-06-24 Sciclone Pharmaceuticals Inc Behandlung von aspergillus-infektionen mit thymosin alpha 1
EP1613340B1 (en) 2003-03-28 2010-05-12 SciClone Pharmaceuticals, Inc. Treatment of aspergillus infections with thymosin alpha 1
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
SI2604620T1 (sl) 2003-05-30 2016-10-28 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Modificirani fluorirani nukleozidni analogi
RU2006105640A (ru) 2003-07-25 2007-09-10 Айденикс (Кайман) Лимитед (Ky) Аналоги пуриновых нуклеозидов для лечения flaviviridae, включая гепатит с
WO2005021007A1 (fr) * 2003-08-28 2005-03-10 Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' Prevention et traitement de l'hepatite virale b
WO2005107742A1 (en) 2004-05-05 2005-11-17 Yale University Novel antiviral helioxanthin analogs
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
PT3109244T (pt) 2004-09-14 2019-06-04 Gilead Pharmasset Llc ¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
EP1976382B1 (en) 2005-12-23 2013-04-24 IDENIX Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
US8337828B2 (en) * 2006-05-02 2012-12-25 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of thymosin alpha 1, alone or in combination with PTX3 or ganciclovir, for the treatment of cytomegalovirus infection
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010042697A1 (en) * 2008-10-08 2010-04-15 University Of Miami Regulation of lymphocytes and uses therefor
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
MX2011006891A (es) 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
WO2010075517A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
US8716012B2 (en) 2009-05-08 2014-05-06 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
HUE034239T2 (en) 2010-03-31 2018-02-28 Gilead Pharmasset Llc Method for Crystallization of (S) -isopropyl 2 - (((S) (perfluorophenoxy) (phenoxy) phosphoryl) amino) propanoate \ t
EP2646453A1 (en) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Compounds
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) * 2012-11-09 2015-10-21 长春海悦药业有限公司 一种含有胸腺法新的药物组合物及其制剂
EP4005560A1 (en) 2013-08-27 2022-06-01 Gilead Pharmasset LLC Combination formulation of two antiviral compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (US07384924-20080610-C00031.png) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
RU94022480A (ru) 1996-07-20
CA2119006A1 (en) 1993-04-01
CZ55194A3 (en) 1994-10-19
GR3024025T3 (en) 1997-10-31
WO1993005806A1 (en) 1993-04-01
ATE152914T1 (de) 1997-05-15
EP0603305B1 (en) 1997-05-14
NO941310D0 (no) 1994-04-12
FI941133A (fi) 1994-03-10
CZ286827B6 (cs) 2000-07-12
FI941133A0 (fi) 1994-03-10
EP0603305A1 (en) 1994-06-29
SG64897A1 (en) 1999-05-25
JPH06510998A (ja) 1994-12-08
RU2104010C1 (ru) 1998-02-10
DE69219782T2 (de) 1997-10-09
TW224053B (US07384924-20080610-C00031.png) 1994-05-21
FI107879B (fi) 2001-10-31
ZA926964B (en) 1993-04-26
AU2644792A (en) 1993-04-27
DK0603305T3 (da) 1997-09-01
US5849696A (en) 1998-12-15
AU667327B2 (en) 1996-03-21
JP3228512B2 (ja) 2001-11-12
HK1021687A1 (en) 2000-06-23
DE69219782D1 (de) 1997-06-19
HU221006B1 (hu) 2002-07-29
HU9400758D0 (en) 1994-06-28
US6001799A (en) 1999-12-14
KR100254082B1 (ko) 2000-09-01
HUT75166A (en) 1997-04-28
NO941310L (no) 1994-04-12
ES2103966T3 (es) 1997-10-01
CA2119006C (en) 2005-08-23
MX9205240A (es) 1993-07-01
US20070218033A1 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
RO111991B1 (ro) Metoda de tratament al hepatitei c si compozitie farmaceutica pentru tratare
US6461605B1 (en) Continuous low-dose cytokine infusion therapy
SK149199A3 (en) Polyethylene glycol-interferon alpha conjugates for therapy of infection
Douglas et al. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C: comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM
Podzamczer et al. Low‐dose interferon alpha combined with zidovudine in patients with AIDS‐associated Kaposi's sarcoma
WO1994001125A9 (en) Composition and method of treating hepatitis b
WO1994001125A1 (en) Composition and method of treating hepatitis b
KR100306024B1 (ko) 인터페론치료에대한무반응자의c형간염치료조성물
Farhat et al. Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B
KR20140035305A (ko) C형 간염 바이러스 감염의 새로운 치료법
KR100394382B1 (ko) 천연사람α-인터페론으로구성된약학조성물
Mauser‐Bunschoten et al. Effect and side‐effects of alpha interferon treatment in haemophilia patients with chronic hepatitis C
Northfelt et al. Continuous, low‐dose therapy with interferon‐α for human immunodeficiency virus (HIV)‐related immune thrombocytopenic purpura
Yabrov It is hazardous to treat HIV patients with interferon-α
AU751199B2 (en) Composition and method of treating hepatitis B
JPH07258109A (ja) C型肝炎の処置法および処置用組成物
Dusheiko New treatments for chronic viral hepatitis B and C
Naoum et al. Treatment of herpes zoster with interferon alpha-2A.
Pockros Current status of immunomodulatory therapies in HCV infection
JP2014528947A (ja) C型肝炎ウイルス感染症の治療のためのアリスポリビル
Emerit et al. Successful Antioxidant Therapy Including Superoxide Dismutase Associated with Antiretroviral Therapy in an HIV-Infected Patient with Hepatitis B-related Cirrhosis